Rhythm Pharmaceuticals (RYTM)

Common Shares

Sell: $79.00|Buy: $97.11|Change: 2.06 (-2.14%)

Open

$95.79

Previous close

$96.23

Trade high

$96.758

Volume

882,559

Year high

$122.20

Year low

$55.31

Dividend yield

–

Market capitalisation

$6.45 bn

P/E ratio

–

ISIN

US76243J1051

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 08/05/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Rhythm Pharmaceuticals	- 2.14
More...

Company profile

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.